Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
53.1M
-
Number of holders
-
104
-
Total 13F shares, excl. options
-
45.8M
-
Shares change
-
+91.8K
-
Total reported value, excl. options
-
$510M
-
Value change
-
-$4.93M
-
Put/Call ratio
-
0.15
-
Number of buys
-
49
-
Number of sells
-
-40
-
Price
-
$11.15
Significant Holders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) as of Q1 2024
120 filings reported holding ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share as of Q1 2024.
ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) has 104 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 45.8M shares
of 53.1M outstanding shares and own 86.24% of the company stock.
Largest 10 shareholders include venBio Partners LLC (9.7M shares), FMR LLC (7.52M shares), Redmile Group, LLC (4.33M shares), Vivo Capital, LLC (4.22M shares), Cormorant Asset Management, LP (3.14M shares), ORBIMED ADVISORS LLC (2.72M shares), Vestal Point Capital, LP (2.61M shares), BlackRock Inc. (2.22M shares), VANGUARD GROUP INC (1.57M shares), and MPM BIOIMPACT LLC (1.27M shares).
This table shows the top 104 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.